pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA
Olema Pharmaceuticals
Olema Pharmaceuticals is a pharma organization headquartered in Chennai, IN. It trades on NYSE under ticker OLMA. Primary therapeutic focus areas include Hormone Receptor Positive Breast Carcinoma, ER+, HER2- Advanced Br
Chennai, IN HQ
2 Employees
Public company Type
OLMA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Chennai, IN
- Employees
- 2
- Programs
- 7
- Drugs
- 17
- Patents
- 8
OP-1250-301
Phase 3 · small molecule · ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
OP-1250-301 for ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy is a Phase 3 program (small_molecule) at Olema Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code OP-1250-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Olema Pharmaceuticals
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
- Status
- active
- Trials
- 1